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CHAPTER 1 
INTRODUCTION 
 
 
1.1 Basic biology and epidemiology of dengue 
1.1.1 Dengue disease 
 
Dengue disease is probably the most important arthropod borne viral disease in 
terms of human morbidity and mortality. Up to one third of the world population is 
at risk of dengue infection. The disease is now highly endemic in more than 100 
tropical countries and the number of cases has been increased dramatically 
during the past decades (WHO, 2009). It remains a major health problem in 
South-east Asia, Central America and the Pacific region, representing one of 
major causes of child death in several countries (Monath, 1994). Among South-
east Asia countries, in the period of 2006-2008 Indonesia was reported to be the 
highest number of dengue with a total of 396196 cases and 3468 deaths case 
fatality rate (CFR) ~1%. The current situation of dengue in Indonesia is stratified 
by World Health Organization (WHO) as the highest epidemic category (WHO, 
2008). 
 
Dengue diseases especially dengue haemorrhagic fever (DHF) and dengue 
shock syndrome (DSS), are serious clinical conditions that occur almost 
exclusively in response to the secondary infection by dengue virus (DENV) 
(Henchal and Putnak, 1990; Thein et al., 1997). In reality, over than 99% of the 
cases of viral haemorrhagic fever worldwide reports are related instead to DHF 
(Rothman, 2004). 
 
Until recently, the highly domesticated Aedes aegypt mosquito represents the 
main vector for the transmission of DENV to human. However, recent 
observation showed that the strong ecological plasticity of Aedes albopictus has 
allowed a further spread of DENV throughout the world (Benedict et al., 2007). 
Moreover, the lack of proper diagnostics and inability to control mosquito 
populations make the disease to be prevalent and to be major public issue in the 
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developing countries. No preventative therapies such as vaccines or anti-viral 
treatments are currently available for dengue disease infections, despite its 
major impact on the world population (Warke et al., 2008). Geographical 
distribution of DENV is mostly found in the tropical and subtropical regions as 
shown in the Figure 1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. World distribution of dengue and Aedes aegypti in 2005 (CDC, 
2005). 
 
 
 
1.1.2 Clinical and pathological findings on dengue virus infection 
 
Four different serotypes of DENV (DENV-1, DENV-2, DENV-3, and DENV-4) of 
the genus Flavivirus have been discovered. The incubation period of DENV 
infection varies from 3-14 days (WHO, 1997). Infections by dengue virus 
produce a spectrum of clinical illness ranging from a non-specific viral syndrome 
to severe and fatal hemorrhagic disease.  
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Dengue fever (DF) is a mild, self-limiting febrile illness typically associated with 
the following symptoms: retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic 
manifestations, leukopenia, and headache. Most of the infected persons recover 
after the acute febrile period without any specific treatment (Bhamarapravati, 
1989; Bhamarapravati et al., 1967; Burke et al., 1988; Gubler, 2006). There is a 
lower risk of death in DENV patients presenting clinical symptoms for DF. 
 
Dengue Haemorrhagic Fever (DHF) is an acute vascular permeability syndrome 
accompanied by abnormalities in haemostatis. The clinical features include 
plasma leakage, bleeding tendency, and liver involvement (Bhamarapravati, 
1989; Bhamarapravati et al., 1967; Burke et al., 1988; Henchal and Putnak, 
1990). After dengue virus infection, there is a continuum from mild DF to severe 
DHF or DSS. It has been estimated that 4-6% of individuals with second 
infection develop severe DHF disease (Halstead, 2007; Mackenzie et al., 2004). 
In the most severe cases, clinical deterioration is characterized by severe 
thrombocytopenia and selective vascular leakage (Oishi et al., 2007). 
Furthermore, according to severity, WHO has divided DHF into 4 grades (I-IV) 
(WHO, 1997). Grade I and grade II are a non-shock DHF. Grade III and grade IV 
are cases of DHF with shock (Malavige et al., 2004). The pathogenesis, 
especially the mechanistic steps toward the manifestation of DHF, is not clearly 
understood. 
 
Dengue shock syndrome (DSS) is associated with a very high mortality (a rate of 
9.3%, increasing to 47% in instances of profound shock). Acute abdominal pain 
and persistent vomiting are early warning signs of impending shock. Suddenly 
hypotention may indicate the onset of profound shock. Prolonged shock is often 
accompanied by metabolite acidosis which may precipitate disseminated 
intravascular coagulation or enhance ongoing disseminated intravascular 
coagulation, which in turn could lead to massive haemorrhage. DSS may be 
accompanied by encephalopathy due to metabolic or electrolyte disturbance 
(Malavige, 2004). 
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1.1.3 Pathogenesis of severe dengue virus infection 
 
It is generally believed that, as in the case for most flaviviruses infection, patients 
who acquire the dengue disease at the first time (primary infection) elicit lifelong 
protective immunity to homologous strains of DENV. Patients exposed for the 
second time (secondary infection) are usually susceptible to heterologous strains 
of DENV (Nielsen, 2009). The term secondary infection refers to the second 
infection by a different DENV strain of a patient who already has finished and 
cleared a first infection by DENV (WHO, 1997). In case of DENV, individuals are 
protected against reinfection with the same serotype but not against the other 
three serotypes that circulate globally. In fact, many epidemiological studies 
have demonstrated that the development of more severe DHF is associated with 
secondary infections with a heterotypic serotype (Burke et al., 1988; Guzman et 
al., 1990; Halstead et al., 1969; Sangkawibha et al., 1984; Thein et al., 1997), 
that led to the widely accepted hypothesis of antibody-dependent enhancement 
(ADE) of DENV infection (Halstead, 2003; Pang et al., 2007; Rothman and 
Ennis, 1999; Sullivan, 2001). 
 
ADE theory has been a long-term thought to play a central role on the 
pathogenesis of severe dengue infection (Halstead, 1970). This theory is based 
on the observations of severe DHF manifestation in children experiencing a 
secondary dengue virus infection which has a different serotype (heterologous) 
of the previous one (Halstead and O’Rourke, 1997). During secondary infection, 
subneutralizing antibodies recognize DENV and form antigen-antibody 
complexes. This complex is recognized by cells expressing Fc receptors (FcR) 
such as monocytes (Mady et al., 1991). This interaction leads to enhanced 
uptake of virus, resulting in an increased number of cells being infected by the 
virus (Littaua et al., 1990, Lei et al., 2001). ADE-mediated infection has been 
reported in many ribonucleic acid (RNA) viruses, including flavivirus and others 
(Suhrbier and La Linn, 2003). However, unlike these viruses, severe dengue 
infections have been uniquely associated with hemorrhage. This observation 
suggests that the hemorrhage found in DHF patients might not be completely 
Introduction  5 
 
 
explained by the ADE hypothesis. Figure 2 shows the current model of DHF 
pathomechanism involving specific T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunological model of DHF pathomechanism. DENV specific 
memory T cells are activated following a secondary infection of the host by 
different DENV serotype. The activated memory T cells rapidly express 
cytokines (such as tumor necrosis factor- TNF-and interferon (IFN-. 
Additionally, DENV specific antibodies increase the viral burden of virus-infected 
cells expressing Fc receptors by ADE mechanism. The increased number of 
viral on antigen presenting cells activates memory T cells. The accumulated 
production of cytokines by memory and naive T cells during a secondary 
infection along with complement activation enhances the effect on vascular 
endothelial cells and lead to plasma leakage (Rothman, 2003 with some 
modifications). 
 
 
 
 
 
 
Introduction  6 
 
 
1.1.4 Virus structure 
 
Dengue virus belongs to the family Flaviviridae (from the Latin flavus, yellow), 
which includes yellow fever virus (YFV), Japanese encephalitis virus (JEV) and 
West Nile virus (WNV). DENV is an arthropod borne (Monath and Heinz, 1996) 
and is a small single-stranded RNA virus which comprised of four distinct 
serotypes (DENV 1-4). Its genome consists of a single open reading frame 
encoding for a large polypeptide which is cleaved by viral and host proteases in 
at least 10 discrete proteins. The N-terminal one quarter of the polypeptide 
encodes the structural proteins core (C), precursor membrane (prM/pM), 
envelope (E), and the remaining part contains seven nonstructural (NS) proteins, 
including large, highly conserved proteins NS1, NS3, and NS5 and four small 
hydrophobic proteins NS2A, NS2B, NS4A, and NS4B (Chambers, 1990; 
Henchal and Putnak, 1990; Zhang, 2003;). Figure 3 shows the gene organization 
of the Flavivirus and its resulting proteins and the location of the major targets of 
immune response. The DENV genome is a single-stranded sense RNA with a 
single open reading frame (ORF, top). The ORF is translated as a single 
polyprotein (middle) that cleavage by viral and host protease to yield the ten viral 
proteins (bottom) (Rothman, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flavivirus genome organization (Rothman, 2004) 
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The NS1 glycoprotein (Mr ~46 kDa) exists in a cell-associated, cell-surface, or 
extracellular nonvirion secreted form in infected mammalian cells (Wingkler, 
1989). In contrast, the remaining NS proteins are localized on the cytoplasmic 
side of the endoplasma reticulum (ER) membrane (Markoff et al., 1994; Falgout 
and Markoff, 1995). Several reports have demonstrated that NS1 is highly 
immunogenic and could induce the production of complement-fixing antibody. 
This antibody can cause a direct complement-mediated lysis of infected target 
cells via interaction with the cell-surface-associated form of NS1 (Costa et al., 
2007). The secretion of a viral NS1 protein that elicits protective immune 
response is an interesting phenomenon in Flavivirus biology. 
 
Clinical study observed the presence of secreted form of NS1 in serum of 
patients during dengue infection (Monath and Heinz, 1996). Furthermore, 
several studies found that DHF patients with a secondary infection developed 
frequently anti-NS1 antibodies indicating that these antibodies may associate 
with the pathomechanism of DHF and DSS (Kuno et al., 1990; Falconar, 1997; 
Valdes et al., 2000). Other studies indicated that anti-NS1 antibodies may confer 
protection against DENV (Henchal et al., 1985; Schlessinger et al., 1993). 
Meanwhile the use of anti-NS1 antibodies as predictor for DHF is focused of 
different clinical studies (Lemes et al., 2005). 
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1.2 Dengue disease and endothelial cells 
1.2.1 Cross-reaction of dengue antibodies with endothelial cells  
 
Dengue haemorrhagic fever is the main cause of mortality in dengue virus 
infection (Valdes et al., 2000). Haemorrhagic syndrome, a feature of DHF/DSS is 
a hematologic abnormality resulting from multiple factors, including 
thrombocytopenia, coagulopathy and vasculopathy related with dysfunction of 
platelet and endothelial cells (Rothman et al., 1999). The clinical symptoms of 
DHF/DSS, which include hemorrhage, thrombocytopenia, increased vascular 
permeability, decreased blood pressure, and hypovolemic shock, strongly 
indicate a disorganization of haemostasis system in this disease. 
 
Endothelial cells and platelets are known to play an important role in regulating 
vessel permeability and maintaining haemostasis (Kaiser et al., 1997). The most 
characteristic feature of DHF/DSS and the best indicator of disease severity is 
plasma leakage that results from structural damage of endothelial cells (Lei et 
al., 2001). Plasma leakage is caused by a diffuse increase in capillary 
permeability and manifests as any combination of hemoconcentration, pleural 
effusion, or ascites. It usually becomes evident on days 3-7 of illness, during 
which time dengue fever resolve (Bhamarapravati et al., 1967; Burke, 1988). 
Plasma leakage occurs systemically, progressing quickly, but will resolve within 
1 to 2 days in patients who receive appropriate fluid resuscitation. No 
subsequent tissue or organ dysfunction is observed. Although perivascular 
edema is obvious, however, no obvious destruction of vascular endothelial cells 
has been reported. It was previously thought that plasma leakage was due to 
altered vascular permeability rather than to structural destruction of endothelial 
cells. The functional alteration of endothelial cells is probably caused via by-
standard effects of cytokine or mediator release in dengue infection. The dengue 
virus can infect endothelial cells in vitro which lead to apoptosis as well as 
production of cytokines and chemokines such as IL-6, IL-8 and regulated upon 
activation normal T cell expressed and secreted (RANTES) (Avirutnan et al., 
1998; Huang et al., 2000) but no infection in biopsies of patients with DHF/DSS 
have been demonstrated. 
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Disturbance of platelet as well as endothelial cell functions by antibodies may 
initiate the clinical manifestations of thrombocytopenia and endothelial 
dysfunction. Lin et al (2002) reported that anti-NS1 antibodies can cross-react 
with non-infected endothelial cells and induce these cells to undergo apoptosis. 
Recent studies showed that anti-NS1 antibodies caused thrombocytopenia in in 
vitro as well as in in vivo mouse model (Chang et al., 2002; Sun et al., 2007). 
 
The endothelium acts as the primary barrier of the circulatory system could 
broadly affect the immune cell function and contribute to dengue pathology 
(Warke et al., 2003). The body releases cytokines that cause the endothelial 
tissue to become permeable which results in hemorrhage and plasma loss from 
the blood vessels. Cytokines are proteins secreted during innate and adaptive 
immunological responses, acting as inflammatory mediators or modulatory 
molecules during several haemorrhagic fevers (Marty et al., 2006). Clinical 
studies support a key role for cytokines in the DHF pathogenesis (Hober, 1993; 
Bethel, 1998; Green, 1999; Braga, 2001; Fink et al., 2006; Azeredo, 2006). 
Endothelial damage and activation were observed in the acute phase of dengue 
virus infection (Cardier et al., 2006; Sosothikul et al., 2007). Apoptosis in 
microvascular endothelial cells from lung and intestine tissues was observed in 
fatal cases of DHF/DSS (Limonta et al., 2007). However, in the recent years a 
number of studies have shown that infection with DENV induces apoptosis in 
vitro and also in vivo (Despres et al., 1996; Marianneau et al., 1999; Couvelard 
et al., 1999; Huerre et al., 2001; Lei et al., 2001). Anti-NS1 antibodies generate 
in mice has been shown to cross-react with human fibrinogen, platelets and 
endothelial cells (Falconar, 1997; Falconar, 2007). The cross reactivity of 
dengue patient sera with endothelial cells have also been demonstrated. 
Endothelial cells were more reactive with DHF/DSS patient sera than DF patient 
sera (Lin et al., 2004). 
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1.2.2 Dengue virus-induced anti-endothelial cell autoantibodies 
 
The binding reactivity of the sera of DHF/DSS with endothelial cells was 
detected by flow cytometric. There were higher percentages of endothelial cells 
reactive with DHF/DSS than those with DF patient sera. Further studies showed 
that platelet or endothelial cell binding activities were inhibited by pretreatment 
with dengue NS1. A molecular mimicry between the dengue virus and 
endogenous self-proteins was proposed to be one of the mechanisms for the 
induction of autoimmunity during dengue virus infection (Lin et al., 2003).  
 
 
 
1.2.3 Immunopathogenetic effects of dengue virus infection on 
endothelial cells  
 
Although the disruption of endothelial barrier is a hallmark of DENV infection, 
however, the exact mechanism is a quite few known. The endothelium is the 
target site for DENV infection-mediated pathology such as vascular permeability, 
capillary fragility (evidenced by positive tourniquet test done in patients), 
bleeding, and coagulopathy and hypovolemic shock during the acute phase of 
DHF/DSS. In vivo, the pathophysiology clinically observed is considered to be a 
result of both direct (viral infection) and indirect (pro-inflammatory cytokines, 
chemokines released by activated leukocytes) effects on endothelial cells. 
Apoptosis of endothelial cells caused by both virus infection and by anti-NS1 
antibodies has been proposed (Andrew, 1978; Avirutnan et al., 1998; Lin et al., 
2002; Huang et al., 2006). 
 
Recently, Cheng et al. (2009) reported several candidate antigens of anti-NS1 
antibodies by proteomic approach. However, the specific endothelial antigen 
reacting with anti-NS1 antibody is not known. Functional studies in the past 
demonstrated that anti-NS1 antibodies are able to cross-react with non-infected 
endothelial cells and trigger the intracellular signaling leading to the production of 
nitric oxide. Nitric oxide (NO) caused upregulation of p53 and Bax and down-
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regulation of pro- and anti-apoptotic factors Bcl-2 and Bcl-xL, respectively, which 
leads to cytochrome-c release and caspase-3 activation (Lin et al., 2002; Lin et 
al., 2004). The activation of caspase-3 has been identified as a key mediator of 
apoptosis of mammalian cells. Furthermore, nuclear factor-κB (NF-B) activation 
was found in endothelial cells after stimulation with anti-NS1 antibodies (Lin et 
al., 2002).  
 
Recently, Naidu et al. (2008) described a direct association between NF-B 
activation pathway and the induction of anti-apoptotic heme oxygenase-1     
(HO-1). Soares et al. (1998) demonstrated that HO-1 inhibits the expression of 
proinflammatory genes like TNF- or IL-1 associated with endothelial activation 
via a mechanism that is associated with the inhibition of NF-B activation 
resulting in the modulation of adhesion molecules like E-selectin, intercellular cell 
adhesion molecule (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). 
Furthermore, Foresti et al. (2003) described that NO potently up regulated HO-1 
in the presence of heme and heme metabolites. Several pathological states are 
characterized by increased NO production and liberation of heme. This 
synergism may ultimately increase the defensive abilities of endothelium to 
counteract cell apoptosis. 
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1.3 Heme Oxygenase (HO) 
1.3.1 Isoforms of HO 
 
Heme oxygenase catalyzes the first and rate-limiting step of heme degradation. 
HO breaks up the heme tetrapyrrole ring to yield equimolar amounts of biliverdin, 
carbon monoxide (CO) and iron (Figure. 3). Biliverdin, in turn, is converted into 
bilirubin by biliverdin reductase in a non-rate-limiting enzyme reaction (Maines, 
1997). Three HO isoforms have been discovered; HO-1, -2 and -3 (Tenhunen et 
al., 1968; Maines et al., 1986). However, the biological significance of a third 
isoform, HO-3, is unclear (McCoubrey et al., 1997).  
 
HO-1 and HO-2 are products of distinct genes. Both isoforms are highly 
conserved throughout evolution and are found in a wide range of organisms 
such as bacteria, fungi, plants and mammalians. Nucleotide sequence homology 
among mammalians (rat, mouse, and human) is >80% or >90% for HO-1 and 
HO-2, respectively (Maines, 1997).  
 
The homology between HO-1 and HO-2 genes is about 43%. The inducible HO-
1 isoform (also known as 32-kDa heat-shock protein), exhibits low basal gene 
expression levels in most cells and tissues. High gene expression levels of HO-1 
are detected in spleen and liver tissue macrophages (Kupffer cells) in which 
senescent erythrocytes are sequestered and destroyed. By contrast, the non-
inducible HO-2 form (36 kDa) exhibits high constitutive gene expression 
preferentially in brain and testis (Maines, 1988; Wagener et al., 1999; Otterbein 
and Choi, 2000). 
 
 
 
1.3.2 Functional significance of HO-1 
 
HO-1 is upregulated by heme, or heme-containing compounds, and also by non-
heme containing compounds that increase the cellular production of reactive 
oxygen species (ROS) in different cells and tissues (Immenschuh and Schröder, 
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2006). Due to this large array of stress stimuli that induce HO-1 gene 
expression, HO-1 has been considered for many years to serve cytoprotective 
functions against oxidative stress (Vile and Tyrell, 1994). In addition, HO-1 has 
been recognized to have anti-inflammatory effects (Poss and Tanegawa, 1997; 
Yachie et al., 1999). Different regulatory mechanisms such as modulation of 
proinflammatory cytokines and activation of T-cells by HO-1 have been observed 
(Otterbein et al., 2003; Kapturczak et al., 2004; Brusko et al., 2005).  
 
The broad spectrum of substances that induce HO-1 suggests that various 
signaling pathways are involved in the regulation of HO-1 gene such as mitogen-
activated protein kinases, protein kinase C, cAMP-dependent protein kinase A, 
or cGMP-dependent protein kinase G (Immenschuh and Ramadori, 2000). 
 
Several studies have been done in regards to the regulation of HO-1 gene 
expression by different stimuli that increase the cellular ROS production 
(Applegate et al., 1991; Choi and Alam, 1996). It has been shown that 
scavengers of ROS such as N-acetyl -cysteine (NAC) inhibit the magnitude of 
HO-1 induction by oxidative stress (Lautier et al., 1992). These findings indicate 
that an increase of intracellular ROS and, thereby, the activation of redox-
dependent signaling pathway play a crucial role for the regulation of HO-1 gene 
expression.  
 
Although the exact mechanism of redox signaling targeted by ROS is not solved 
yet, changes of the cellular redox state seem to be responsible for the 
modification of specific regulatory protein kinases and phosphatases leading to 
the alteration in the regulation of gene expression (Finkel, 1998). 
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Figure 4. The enzymatic reaction catalyzed by heme oxygenase enzymes. 
 
 
 
1.3.3  Physiological function of HO-1 
Antioxidant enzyme levels are sensitive to oxidative stress. Both increased and 
decreased levels have been reported in different disease in which an 
enhancement of ROS is a cause or a consequence of the illness (Gebicki, 1997).  
Major functions of HO enzyme activity comprise degradation of the prooxidant 
heme and production of CO and bilirubin, thereby providing protection of organs 
and tissue against oxidative stress (Abraham et al., 1988; Maines, 1997). More 
recently, accumulating evidence indicates that HO-1 is an important modulator of 
the inflammatory response possibly via the generation of the second messenger 
gas CO (Otterbein et al., 2000; 2003). An anti-inflammatory function of HO-1 has 
been shown in experimental models of acute complement-dependent pleurisy 
and heme-induced inflammation of various organs (Willis et al., 1996; Wagener 
et al., 1999). However, modulation of HO-1 may not only serve as a therapeutic 
target in inflammatory disease, but also has therapeutic implications in organ 
transplantation. HO-1 has been demonstrated to play a protective role in several 
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experimental transplantation models, in which elevated HO activity prevents the 
development of vascular lesions, intra-graft apoptosis, ischemia/reperfusion 
injury, and significantly prolongs allograft survival (Soares et al., 1998; Hancock 
et al., 1998; Amersi et al., 1999; Immenschuh and Ramadori, 2000). 
 
 
 
1.3.4 Signaling pathway of HO-1 
 
Stimulation of the HO-1 gene by most, if not all, stimuli is primarily controlled at 
the transcriptional level.  A variety of regulatory elements (RE) and transcription 
factors (TF) have been demonstrated to be involved in this process (Choi and 
Alam 1996). The broad spectrum of substances  that induce HO-1 suggests that 
various signaling pathways are involved in the regulation of this gene such as 
mitogen-activated protein kinases (MAPK), protein kinase C (PKC), cAMP-
dependent protein kinase A (PKA), or cGMP-dependent protein kinase G (PKG) 
(Immenschuh and Ramadori, 2000). 
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1.4 Objectives of the study 
 
Understanding the role of anti-NS1 antibodies binding on endothelial cells and its 
functional signaling consequence during dengue virus infection may help to 
understand the cause of vascular leakage in DHF patients which may have 
therapeutic benefits. 
 
The objectives of this study were (1) to study the regulation of the anti-
inflammatory gene, HO-1 on human umbilical vein endothelial cells (HUVEC) 
after stimulation with anti-NS1 antibodies derived from DHF patients, (2) to 
identify the prominent cellular signaling pathway that was activated or regulated 
by HO-1 gene, and (3) to characterize the target antigen on endothelial cell 
surface that recognized by anti-NS1 antibodies. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
2.1  Materials 
2.1.1  Chemicals and reagents 
 
Acrylamide/bisacrylamide 30%,    Roth, Karlsruhe, Germany 
Bromophenol blue      Merck, Darmstadt, Germany 
Bovine serum albumin (BSA)   Serva, Heidelberg, Germany 
Cell culture lysis reagent 5x    Promega, Madison, WI, USA 
Chloroform       Roth, Karlsruhe, Germany 
Dimethylsulfoxid (DMSO)     Sigma-Aldrich, Munich, Germany 
Dithiothreitol       Sigma-Aldrich, Munich, Germany 
Dry milk       Sucofin, Zeven, Germany 
Ethanol (100%)     Roth, Karlsruhe, Germany 
Ethidium bromide      Dianova, Hamburg, Germany 
Ethylenediamine tetraacetic acid (EDTA)  Merck, Darmstadt, Germany 
Extract of yeast powder     Merck, Darmstadt, Germany 
Glycerol       Sigma-Aldrich, Munich, Germany 
Glycin       Sigma-Aldrich, Munich, Germany 
Glycogen       Roche, Basel, Switzerland 
Methanol       Roth, Karlsruhe, Germany 
Penicillin/Streptomycin     Merck, Darmstadt, Germany 
Phenol       Sigma-Aldrich, Munich, Germany 
PMSF       Merck, Darmstadt, Germany 
Ponceu S       Serva, Heidelberg, Germany 
Potassium acetate      Sigma-Aldrich, Munich, Germany 
Sodium acetate      Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS)    Sigma-Aldrich, Munich, Germany 
Tetra-methylethylendiamine    Serva, Heidelberg, Germany 
Tris base       Sigma-Aldrich, Munich, Germany 
Triton-100       Sigma Aldrich, Munich, Germany 
Materials and Methods 18 
 
 
Yeast extracts      Difco, Detroit, MI, USA 
Tween 20       Sigma-Aldrich, Munich, Germany 
 
All other standard reagents were from Sigma-Aldrich, if not indicated otherwise. 
 
 
2.1.2  Pharmacological compounds 
 
Bacitracin       Sigma-Aldrich, MO, USA 
H2DCFDA       Sigma-Aldrich, Munich, Germany 
Fluorescent labeled albumin   Sigma Alrich, MO, USA 
Fibronectin       Sigma-Aldrich, Munich, Germany 
Heme        Sigma- Alrich, Munich, Germany 
LY294002       Calbiochem, La Jolla, CA, USA 
N-acetylsystein Sedico Pharmaceutical, Cairo, 
Egypt 
Protein G sepharose CL-4B bead   Pharmacia, Uppsala, Sweden 
Phorbol 12-myristate 13-acetate (PMA)   Sigma-Aldrich, Munich, Germany 
SB203580       Calbiochem, La Jolla, CA, USA 
Sulfo-NHS-Kc Biotin  Thermo Scientific, Rockford, IL, 
USA 
TNF-α       Roche, Basel, Switzerland 
TPA        Sigma-Aldrich, Munich, Germany 
Wortmannin       Calbiochem, La Jolla, CA, USA 
 
 
2.1.3 Markers 
 
Rainbow TM protein molecular weight   Amersham, Freiburg, Germany 
Biotin Marker      Cell Signaling, Beverly, MA, USA 
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2.1.4  Kits 
 
Annexin V Kit BD Pharmingen, San Diego, CA, 
USA 
BCA protein assay kit Thermo Scientific, Rockford, IL, 
USA. 
ECL cheluminescence kit Calbiochem, Darmstadt, 
Germany 
Pure Melon™ gel IgG purification kit  ThermoScientific, Rockford, IL, 
USA. 
Chemiluminescence detection system   Millipore, Billerica, MA, USA 
 
 
2.1.5  Materials of cell culture 
 
Dulbecco’s Modified Eagle’s medium   Gibco, Grand Island, NY, USA 
Endothelial cell basal medium (EBM)  PromoCell, Heidelberg, Germany 
Fetal bovine serum (FBS)     Biochrom KG, Berlin, Germany 
Fetal calf serum (FCS)     Biochrom KG, Berlin, Germany 
Ficoll-Paque       Amersham, Freiburg, Germany 
Gentamycin       PromoCell, Heidelberg, Germany 
Hepes       Gibco, Gaithersburg, MD, USA 
RPMI 1640       Gibco, Gaithersburg, MD, USA 
Sodium-pyruvate      Gibco, Gaithersburg, MD, USA 
Trypsin-EDTA (1X) (w/o Ca & Mg)   Gibco, Grand Island, NY, USA 
Tissue culture dish 6 cm     Falcon, Heidelberg, Germany 
Tissue culture flash      Falcon, Heidelberg, Germany 
Tissue culture 6-well plate  
(surface area 9.6 cm2)  Greiner, Frickenhausen, 
Germany 
Transwell  Costar, Cole Parmer, IL, USA 
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2.1.6  Cell cultures 
 
HUVEC human endothelial cells   ATCC, Walkerville, MD, USA 
Eahy 926 ECV304 human endothelial cells  ECCC, Braunschweig, Germany 
U 937 monocytic cells line     ATCC, Manassas, VA, USA 
 
 
 
2.1.7  Antigen and antibodies 
Primary antibodies: 
 
Mab anti-NS1 (clone DN 2)    Abcam, Cambridge, UK 
Mab againts HO-1     Stressgen, Victoria, BC, Canada 
GAPDH      HyTest, Turku, Finland 
PDI-antibody clone 77     Abcam, La Jolla, CA, USA 
RL 90 mab against PDI     Novus Biological, CA, USA 
 
Mabs against PECAM-1 (clone GI18), CD177 (7D8), and CD31 were produced 
and characterized in our laboratory. 
Purified IgG was isolated from secondary dengue infected patient sera and 
healthy donor sera.  
 
 
Secondary antibodies  
 
Goat anti-rabbit IgG-HRP  Acris Antibodies, Hiddenhausen, 
Germany  
Goat anti-mouse IgG-HRP  Acris Antibodies, Hiddenhausen, 
Germany 
Goat anti-human IgG-HRP  DPC Biermann, Bad Nauheim, 
Germany 
Rabbit anti-mouse IgG-HRP Acris Antibodies, Hiddenhausen, 
Germany 
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Goat anti-mouse FITC    Invitrogen, Carlsbad, CA, USA 
Streptavidin horseradish peroxidase Amersham Life Science, 
Arlington, IL, USA 
 
Antigen 
 
NS1 antigen  Prospec-Tanytechno Gene, 
Rehovot, Israel 
 
2.1.8 Other materials 
 
3 mm Whatman paper  Schleicher and Schuell, Dassel, 
Germany 
Lumi-LightPLUS western blotting substrate  Roche, Mannheim, Germany 
Polyvinylidene fluoride membranes (PVDF)  Millipore, Bedford, MA, USA 
 
 
2.1.9  Instruments 
 
AMAXA electroporation system    Amaxa, Koln, Germany 
Blotting-semidry Whatman    Biometra, Göttingen, Germany 
Centrifuge: RC5C      Sorvall, Wiesloch, Germany 
Densitometry Alpha Innotech, San Leandro, 
CA, USA 
ELISA reader     Bio-rad, Munich, Germany 
FACS Calibur BD Pharmingen, San Diego, CA, 
USA 
Fluorometry       Beckmann, Munich, Germany 
Fluorescence microplate reader  Bio-Tek, Bad Friedrichshall, 
Germany 
Fluorchem FC2 gel documentation system Bio-Tek, Bad Friedrichshall, 
Germany 
Hettich Rotixa/RP      Hettich, Tuttlingen, Germany 
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Hettich Mikro 22R      Hettich, Tuttlingen, Germany 
Electrophoresis apparatus     Bio-Rad, Munich, Germany 
Incubator CO2      Heraeus, Hanau, Germany 
Laminair HB2448      Heraeus, Hanau, Germany 
Microscope Axiovert 10     Zeiss, Oberkochen, Germany 
Spectrophotometer      Beckmann, Munich, Germany 
Nanodrop spectrophotometer  Biocompare, San Francisco, CA, 
USA 
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2.2 Methods 
2.2.1 Sample collection 
 
Serum samples were obtained from the Cipto Mangunkusumo Hospital, Jakarta 
Indonesia. The serum samples were collected from confirmed cases of dengue 
virus infected patients (n=16) during dengue outbreak in 2007. Serum samples 
were selected from patients who were classified as having secondary dengue 
virus infection according to the WHO criteria (WHO, 1997). All serological 
characterizations to identify dengue virus infection and to discriminate between 
primary and secondary infection were done at the Cipto Mangunkusumo 
Hospital, Jakarta. WHO evaluated diagnostic test (Panbio Dengue IgM Capture 
ELISA and Panbio Dengue Duo Casette) was used. Serum samples from 
healthy donors were used as control (n=5).  
 
 
 
2.2.2 IgG purification 
 
IgG was isolated from serum samples using Immuno Pure Melon™ gel IgG 
purification kit. 500 µl Melon gel was added to the column and centrifuge as 
recommended by the manufacturer. After washing with 300 µl purification buffer, 
500 µl of diluted serum in gel purification buffer (1:10) was added to the gel and 
mixed end-over-end for 5 minutes. The gel then centrifuged and purified IgG was 
then collected in a collection tube. IgG concentration was determined by a 
nanodrop spectrophotometer.  
 
 
 
2.2.3 Determination of anti-NS1 antibodies by solid phase ELISA 
 
Antibody against NS1 antigen in patient sera was analyzed by the solid phase 
ELISA, according to Vasquez et al. (1997). Microtiter wells were coated with 
50 µl of recombinant NS1 antigen (5 µg/ml) in 0.1 M bicarbonate buffer, pH 9.5. 
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After blocking with 1% BSA in phosphate-buffered saline (PBS), diluted serum 
sample (1:50 in blocking buffer) was added and incubated for 1 h at 37oC. Wells 
were washed 5 times with 200 µl PBS 0.1% Tween 20 phosphate-buffered 
saline tween (PBST), 100 µl of horse radish peroxidase labeled goat anti-human 
IgG was added for 1 h at 37oC. Reaction was measured in ELISA reader. 
Sample was considered positive if the OD492 > 0.3. 
 
 
 
2.2.4 Cell culture preparation 
 
HUVEC were cultured in fresh endothelial basal medium (EBM) supplemented 
with hydrocortisone (1 mg/ml), gentamycin sulphate (50 mg/ml), amphotericin-B 
(1 μl/ml), and 2% fetal calf serum (FCS). Human monocytic cells line U937 were 
grown in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin. 
Human EA.hy 926 endothelial cells line was maintained in DMEM supplemented 
with 10% FCS and 100 IU/ml penicillin and 100 μg/ml streptomycin. Cell cultures 
were maintained until confluence at 37oC in a controlled environment of 100% 
humidity and 5% CO2. 
 
 
 
2.2.5 Cell culture stimulation  
 
Aliquots of HUVEC in six-well flat bottom plates containing 2 ml EBM were 
stimulated with different concentrations of mab anti-NS1 (2-20 µg/ml) and 
different time periods (1-48 h). After washing with 0.9% NaCl, cells were lysed 
with 200 µl lysis buffer containing 50 mM tris, 150 mM NaCl, 1% triton x-100 and 
2 mM phenylmethylsulfonyl fluoride (PMSF). The endothelial cell lysate was then 
centrifuged for 5 min at 13.000 g at 4oC and the protein concentration of the 
supernatant was determined by bicinchoninic acid (BCA) protein assay kit. 
Endothelial proteins were used for western blotting (see 2.2.6). 
Materials and Methods 25 
 
 
For the analysis of sera from dengue virus infected patients, purified IgG from 
dengue virus infected patient (10 µg/ml) was added either to HUVEC or U937 
cells for 18 h. Heme (10 µg/ml in DMSO) was used as a positive control. In some 
experiment, HUVEC were treated with mab anti-NS1 (10 µg/ml) and DHF IgG 
(10 µg/ml) in the presence of NS1 antigen (10 µg/ml). 
 
In some experimental setting, HUVEC were treated with phosphatidylinositol 
3-kinase (pI3K) inhibitors (wortmannin, LY294002 and p38 inhibitor, SB203580 
in a concentration of 10 µM for 30 min prior to incubation with mab anti-NS1 (10 
µg/ml) and DHF IgG (10 µg/ml) for 18 h. 
 
In some experimental setting, HUVEC were growth as mentioned above until 
confluence. After confluence HUVEC were stimulated with 4 µl 2 mM bacitracin 
and mab anti-RL-90 (10 µg/ml) for 18 h and lysed.  
 
 
 
2.2.6  Western blotting analysis 
 
Total endothelial protein (5 µg) was incubated for 5 min at 95oC using non 
reduced loading buffer. Total endothelial protein was separated on 12% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
electroblotted onto polyvinylidene difloride (PVDF) membranes. After blocking 
with Tris-buffer saline containing 5% skim milk, 50 mM Tris-HCl (pH 7.6), 
150 mM NaCl, and 0.1% Tween 20 for 1 h at room temperature, membranes 
were incubated with antibody against HO-1 (1:2,000 dilution), detected with 
peroxidase labelled goat anti-rabbit IgG (dilution 1:10,000) The enhanced 
chemiluminescent (ECL) chemiluminescent kit detection system was applied for 
detections; as recommended by the manufacturer. 
 
In the control experiment strips were stained with antibody against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; dilution 1:10,000). The 
signals were visualized with the Fluorchem FC2 gel documentation system. 
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2.2.7 Immunoprecipitation 
 
Human EA.hy 926 endothelial cells were maintained in DMEM supplemented 
with 10% FCS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. After 
confluence, 2 x 108 cells were washed three times with PBS and incubated with 
1 ml Sulfo-NHS_LC Biotin (1 mg/ml) for 30 min on ice. Labeled cells were 
resuspended in 200 µl lysis buffer containing 50 mM tris, 150 mM NaCl, 
1% triton x-100, and 2 mM phenylmethylsulfonyl fluoride (PMSF). 
 
After centrifugation at 10,000 g for 10 min, cell lysates were precleared for 30 
min with 50 μl of 20% protein G-Sepharose CL-4B beads in the presence of 
33.3 µl normal human serum for 30 min. Aliquots of 50 µl precleared cell lysates 
were incubated with 5 µg/ml control mouse IgG (mab 7D8; 5 µg/ml), mab anti-
NS1 (DN 2; 5 µg/ml), anti PDI RL-90; 5 µg/ml, anti-PECAM-1 (clone Gi18, 
5 µg/ml), or 50 µl human serum overnight at 4oC.  
 
Immunocomplexes were washed five times with immunoprecipitation buffer (IPB; 
10 mM Tris HCl at pH 7.4). Bound proteins were released by boiling in SDS 
buffer for 5 minutes at 95oC. After centrifugation at 10,000 g for 2 min, samples 
were analyzed by SDS-PAGE and blotted on PVDF membrane as described 
above. Membrane was incubated with 8.3 µl streptavidin horseradish peroxidase 
secondary antibody (1:8,000 dilution) for 30 min at room temperature. After 
washing, precipitated protein was detected by using ECL chemiluminescence kit 
as recommended by the manufacturer. 
 
In some experimental setting a preclearing procedure prior to 
immunoprecipitation was performed. The cell lysates for immunoprecipitation 
were prepared as described above. After centrifugation at 10,000 g for 10 min, 
cell lysates were precleared for 30 min with 50 μl of 20% protein G-Sepharose 
CL-4B beads in the presence of 33.3 µl normal human serum for 30 min. 
Aliquots of 50 µl precleared cell lysates were incubated with 10 µl DHF IgG 
(5 µg/ml). Preclearing with DHF Ig was repeated 3 times. After preclearing, the 
cell lysates were incubated with mab anti-PDI and anti-CD31 (as control) at 4oC 
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overnight. Immunocomplexes were washed five times with washing buffer (IPB; 
10 mM Tris HCl at pH 7.4). Bound proteins were released by boiling in SDS 
buffer for 5 minutes at 95oC. After centrifugation at 10.000 g for 2 min, samples 
were analyzed by SDS-PAGE and blotted on PVDF membrane as described 
above. Membrane was incubated with 8.3 µl streptavidin horseradish peroxidase 
secondary antibodies (1:8,000) for 30 min at room temperature. After washing, 
precipitated protein was detected by using an enhanced ECL 
chemiluminescence kit as recommended by the manufacturer. 
 
 
 
2.2.8 Flow cytometry analysis 
2.2.8.1 Analysis of cells apoptosis  
 
HUVEC were treated with mab anti-NS1 (10 µg/ml) and DHF (10 µg/ml) for 18 h. 
After washing with PBS, cells were resuspended in binding buffer (10 mM 
Hepes, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4). Aliquots of 2 x 104 cells were 
incubated with 5 µl fluorescein labeled annexin V in 100 µl binding buffer at room 
temperature for 15 min in the dark. Labelled cell were analyzed by flow 
cytometry. 
 
 
 
2.2.8.2 Analysis of ROS production 
 
For the measurement of ROS in HUVEC, the green fluorescence dye (5,6-
carboxy-2',7'-dichlorodihydrofluoresceine diacetate (carboxy-H2DCFDA) in 
ethanol was used as recommended by the manufacturer. Aliquots of HUVEC in 
six-well flat bottom plates containing 2 ml EBM were stimulated with 10 µg/ml of 
mab anti-NS1 and incubated for 18 h. Subsequently, 3 µl of 10 μM carboxy-
H2DCFDA was added for 20 min. As positive control, 10 μM 
tetradecanoylphorbol 13-acetate (TPA) was used. The cells were washed 3 
times with PBS (pH 7.4 at 37°C). The presence of fluorescent dye in cells was 
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detected with flow cytometry. In addition, the inhibition of ROS production with 
NAC was measured by flow cytometry. In brief, aliquots of HUVEC in six-well flat 
bottom plates containing 2 ml EBM were treated with different NAC 
concentrations (10-30 mM/ml) for 30 min. After washings with 0.9% NaCl, cells 
were further incubated with fresh serum free EBM and then stimulated with mab 
anti-NS1 (10 µg/ml) and patient IgG (10 µg/ml) for 18 h. 
 
 
 
2.2.8.3 Analysis of antibody binding on endothelial cells 
 
In some experiments, HUVEC cells were untreated or treated with 2 µg/ml TNF-
 for 1 h. Cells were washed using EBM serum free medium and incubated with 
mab anti-NS1(10 µg/ml) and DHF IgG (10 µg/ml) for 18 h. After stimulation cells 
were washed using cold PBS and incubated with fluorescein conjugated 
secondary antibodies and analyzed by flow cytometry. 
 
 
 
2.2.9  Analysis of endothelial permeability 
 
For the measurement of endothelial permeability, HUVEC were grown on 
gelatin-coated Costar transwell and were treated with mab anti-NS1 (10 µg/ml) 
and patient IgG (10 µg/ml) for 18 h. Thereafter, fluorescent labeled albumin 
(40 ng/ml) was added to the luminal chamber. After a period of times, samples 
were collected from the bottom of chambers and analyzed by fluorometry. 
 
 
 
 
 
 
Materials and Methods 29 
 
 
2.2.9  Quantification analysis 
 
Signals from Western blots were evaluated by videodensitometry scanning and 
quantification with Imagequant software. The relative densities of bands were 
expressed as fold-induction normalized to GAPDH from at least three 
independent experiments.  
 
 
 
2.2.10  Statistical analysis 
 
Statistical difference was analyzed by Student’s t test and presented as mean 
values ± S.E. from at least three independent experiments. A value of p ≤ 0.05 
was considered as was statistically significant. 
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CHAPTER 3 
RESULTS 
 
 
3.1 Anti-NS1 antibodies in dengue virus infected patients 
 
The presence of anti-NS1 antibodies in the serum of patients with secondary 
infection from both DF and DHF patients during acute infection was analyzed 
using a solid phase ELISA. Sample was considered positive if the OD492 value > 
0.3. 
 
Anti-NS1 antibodies were detected in eight (50%) serum samples from DF/DHF 
patients (Table 1). Anti-NS1 antibodies were detected only in patients with 
secondary type of infection, while all serum samples from healthy donors were 
negative (Table 2). The result also demonstrated that the presence of anti-NS1 
antibodies of DHF patients is greater than DF patients. Anti-NS1 antibodies were 
detected in six serum samples of DHF patients with secondary infection, while 
anti-NS1 antibodies of DF patients with secondary infection were detected only 
in two serum samples. 
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Table 1. Determination of anti-NS1 antibodies of DF and DHF patients by solid 
phase ELISA. Sample was considered positive if the OD492 > 0.3. 
 
 
 
 
 
 
Sample 
Code 
Dengue Virus Infection 
Category 
Anti-NS1 antibodies 
(OD492 value) 
D1 DHF stadium I 0.738 
D2 DHF stadium I 0.979 
D3 DHF stadium I 0.191 
D4 DHF stadium I 0.979 
D5 DHF stadium I 0.228 
D6 DF 0.639 
D7 DF 0.294 
D8 DHF stadium I 1.284 
D9 DHF stadium I 0.260 
D10 DHF stadium I 0.297 
D11 DHF stadium I 0.218 
D12 DHF stadium II 0.856 
D13 DHF stadium I 1.373 
D14 DHF stadium I 0.228 
D15 DF 0.268 
D16 DHF stadium I 0.764 
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 Table 2. Determination of anti-NS1 antibodies of healthy donors by solid phase 
ELISA. Sample was considered positive if the OD492 > 0.3. 
 
 
 
 
 
 
3.2  The influence of anti-NS1 antibodies on the regulation of HO-1 
 
To investigate the mechanism of how HO-1 expression is regulated on 
endothelial cells, the expression of HO-1 in HUVEC that were treated with mab 
anti-NS1, IgG from DHF patient with positive NS1 (DHF IgG) by immunoblotting 
were examined, IgG from healthy donor (normal IgG) was run as control. As 
shown in Figure 5A, treatment HUVEC with mab anti-NS1 and DHF IgG 
markedly-increased HO-1 protein expression in a dose-dependent manner with a 
maximum of 10 µg/ml. In addition, anti-NS1 antibody-induced HO-1 protein 
levels in time-dependent with a maximum level of expression after 18 h (Figure 
5B). These results indicate that anti-NS1 antibodies in dengue virus infected 
patients are capable to upregulate the anti-apoptotic HO-1 protein expression on 
endothelial cells. 
 
 
Sample 
Code 
Dengue Virus Infection 
Category 
Anti-NS1 antibody 
(OD492 value) 
N1. Healthy donor  0.128 
N2. Healthy donor 0.179 
N3. Healthy donor  0.056 
N4. Healthy donor  0.079 
N5. Healthy donor  0.104 
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Figure 5. Influence of anti-NS1 antibodies on HO-1 upregulation in HUVEC. 
HUVEC were treated with mab anti-NS1, DHF IgG, and normal IgG in different 
antibody concentrations (A) and different stimulation times (B).  
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For comparison, the effect of these stimuli in endothelial was also determined on 
IgG from DHF patient with negative NS1 that run parallel with IgG from DHF 
patient with positive NS1, and mab anti-NS1. Heme and normal IgG were used 
as positive and negative control, respectively. No upregulation was observed 
when endothelial cells were treated with purified IgG from sera DHF patients 
without anti-NS1 antibodies. In contrast, significance upregulation was detected 
with purified IgG containing anti-NS1 antibodies. Similar result was obtained with 
mab anti-NS1 (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Anti-NS1 antibodies induce HO-1 upregulation in HUVEC. No 
upregulation was observed when cells treated with purified IgG from serum of 
DHF patient without anti-NS1 antibodies. In contrast, significance upregulation 
was detected with purified IgG containing anti-NS1 antibody. Similar result was 
obtained with mab anti-NS1. The relative band densities were expressed as fold-
induction, normalized to GAPDH band from three independent experiments.  
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To verify the specificity of HO-1 upregulation in endothelial cells, human 
monocytic cells line U937 were treated with IgG from DHF patient with negative 
NS1, IgG from DHF patient with positive NS1, and mab anti-NS1. Positive and 
negative controls were heme and normal IgG, respectively. No upregulation of 
HO-1 by mab anti-NS1 or DHF IgG was observed in these cells (Figure 7). 
 
 
 
Figure 7. Anti-NS1 antibodies did not induce HO-1 upregulation in U937 
cells. There was no upregulation of HO1 when U937 cells were treated with 
purified IgG from serum of healthy donor, DHF IgG NS1 negative, DHF IgG NS1 
positive, mab anti-NS1 antibodies. The relative band densities were expressed 
as fold-induction, normalized to GAPDH band from three independent 
experiments.  
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3.3  Inhibition of anti-NS1 antibody-mediated HO-1 induction by NS1 
antigen 
 
To investigate whether HO-1 upregulation induced by anti-NS1 antibodies alone 
or by antigen-antibody complex, NS1 antigen was used as an inhibitor. 
Upregulation of HO-1 was detected when endothelial cells were stimulated with 
both NS1 antigen and mab anti-NS1. In contrast, NS1 antigen blocked the anti-
NS1 antibodies binding on endothelial cells and abolished the upregulation of 
HO-1 activity, no upregulation of HO-1 was detected when endothelial cells were 
stimulated with both NS1 antigen and anti-NS1 antibody, simultaneously 
(Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Inhibition of anti-NS1 antibody-mediated HO-1 induction by NS1 
antigen. HUVEC were treated with DHF IgG (10 µg/ml) and mab anti-NS1 
(10 µg/ml) in the absence or presence of purified NS1 antigen (10 µg/ml) for 
18 h. After cell lysed, HO-1 expression was analyzed as described in figure 
above. The relative band densities were expressed as fold-induction, normalized 
to GAPDH band from three independent experiments. 
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3.4  Anti-NS1 antibodies activate HO-1 via pI3K pathway 
 
The pI3K signaling pathway has recently been demonstrated to be involved in 
the induction of HO-1 gene expression (Martin et al., 2004). To evaluate the 
regulatory role of this pathway for the anti-NS1 antibody-dependent induction of 
HO-1 expression various pharmacological inhibitors were tested. Upregulation of 
HO-1 expression by anti-NS1 antibodies was markedly reduced by pretreatment 
with the pI3K inhibitors, LY294002, and wortmannin (Figure 9).  
 
By contrast, pretreatment with the p38 inhibitor SB203580 did not affect anti-NS1 
antibody-dependent induction of HO-1. These data suggest that the pI3K 
signaling pathway plays a major regulatory role for the induction of HO-1 by anti-
NS1 antibody. HO-1 induction is a crucial mechanism of resistance against 
oxidative stress, and understanding the signaling pathways involved in HO-1 
induction will help develop new strategies for the prevention and treatment of 
diseases associated with oxidative stress. The data suggest that the pI3K 
signaling pathway plays a major regulatory role for the induction of HO-1 by anti-
NS1. 
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Figure 9. Anti-NS1 antibodies activate HO-1 on endothelial cells via pI3K 
pathway. HUVEC were incubated with different pI3K inhibitors LY294002 
(10 μM/ml), wortmannin (10 μM/ml) and p38 inhibitor SB203580 (10 μM/ml) for 
30 min prior to incubation with mab anti-NS1 and DHF IgG for 18 h. Cells were 
lysed and HO-1 expression was analyzed by immunoblotting as described. The 
relative band densities were expressed as fold-induction, normalized to GAPDH 
band from three independent experiments.  
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3.5  Anti-NS1 antibodies increase accumulation of cellular ROS  
 
In order to investigate the signaling pathway on anti-NS1 antibody-induced 
apoptosis, ROS production was monitored in HUVEC. The histograms and the 
percentages of ROS production are shown in Figure 10. Treatment with anti-NS1 
antibodies and DHF IgG caused a prominent increased of ROS expression as 
demonstrated by both the percentages of positive cells and the mean 
fluorescence intensity from flow cytometry. In the control experiment, no positive 
staining was observed with normal IgG. Pretreatment HUVEC with NAC 
decreased ROS expression in these cells. NAC is cysteine analog commonly 
used to treat acetaminophen overdose (Kelly, 1998), NAC can protect against 
ROS through the restoration of intracellular glutathione (Juurlink and Paterson, 
1998; Ratan et al., 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Anti-NS1 antibodies induce ROS production on endothelial cells. 
HUVEC were stimulated with DHF IgG (10 µg/ml) and mab anti-NS1 (10 µg/ml) 
for 18 h in the presence or absence of NAC (30 mM), TPA was run as positive 
control. Thereafter, membrane-permeable fluorescence dye carboxy-H2DCFDA 
was added and incubated for 20 min.  
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To determine whether ROS as potential secondary messengers would be 
involved in HO-1 upregulation in HUVEC, the effect of antioxidant NAC on anti-
NS1 antibodies induction of HO-1 was examined. Pretreatment with NAC 
decreased anti-NS1 antibody-dependent HO-1 upregulation in a dose-dependent 
manner (Figure 11). This result suggests the involvement of ROS on the 
induction of HO-1 by anti-NS1 antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effect of NAC on HO-1 upregulation induced by anti-NS1 
antibodies. HUVEC were treated with NAC at concentrations of 10, 20, and 
30 mM for 30 min prior to incubation with mab anti-NS1 and DHF IgG. Cells 
were lysed and analyzed by immunoblotting as described. The relative band 
densities were expressed as fold-induction, normalized to GAPDH band from 
three independent experiments.  
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3.6  Anti-NS1 antibodies induce apoptosis of endothelial cells 
 
The ability of anti-NS1 antibodies to induced endothelial cells apoptosis should 
be tested. HUVEC were treated with mab anti-NS1, DHF IgG. Mab anti-CD177 
and normal IgG were run as controls. Cells apoptosis was measured using flow 
cytometry, the histograms and the percentages of apoptotic cells are shown in 
Figure 12. Cells apoptosis was inducible by mab anti-NS1 and DHF IgG. In the 
control, normal IgG and mab anti-CD177 did not induce cell apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Anti-NS1 antibodies induce apoptosis of endothelial cells. 
HUVEC were treated with mab anti-NS1 (2 µg/ml), and DHF IgG (2 µg/ml). As 
negative controls, mab anti-CD177 (5 µg/ml) and normal IgG (5 µg/ml) were 
used. After incubation for 18 h cells were analyzed by flow cytometry.  
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3.7  Anti-NS1 antibodies binding onto endothelial cells  
 
To characterize the binding site of anti-NS1 antibodies, flow cytometry analysis 
with resting and activated endothelial cells was performed. The histograms and 
the percentages of binding cells are shown in Figure 13. DHF IgG reacted with 
primary HUVEC as well as with endothelial cell line EaHy. These reactions 
increased after stimulating these cells with TNF-. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Flow cytometry analysis of anti-NS1 antibodies binding onto 
endothelial cells. HUVEC and Eahy cells were treated with DHF IgG (10 µg/ml) 
and mab anti-NS1 (10 µg/ml) before and after stimulation with TNF(2 µg/ml). 
After washing bound IgG was detected using fluorescence labeled secondary 
antibody by flow cytometry. Isotype control was run in parallel. 
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3.8  Anti-NS1 antibodies of DHF patients react with PDI antigen on 
endothelial cells 
 
To investigate the binding of anti-NS1 antibodies to protein disulfide isomerase 
(PDI) on endothelial cells, immunoprecipitation of biotinylated Eahy cells with 
mab anti-NS1, anti-PDI, and DHF IgG was performed. Anti-NS1 antibodies 
bound to membrane protein at molecular weights 62-72 kDa, corresponding to 
the molecular weight of PDI (Figure 14). Similar band was also found by 
immunoprecipitation with anti-PDI. To confirm the identity of PDI preclearing 
experiments were performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Immunoprecipitation analysis of anti-NS1 antibodies with 
endothelial cells. A) Eahy cells were labelled with biotin, lysed and precipitated 
with mab anti-NS1 (5 µg/ml), anti-PDI (5 µg/ml), normal IgG (5 µg/ml), and DHF 
IgG (5 µg/ml). Immunoprecipitates were separated on 7.5% SDS-PGE under 
reducing conditions. After blotting, antigens recognized by antibodies were 
visualized by streptavidin chemiluminescence system. B) Biotin labelled Eahy 
cell lysates were precipitated extensively (three times) with DHF IgG (5 µg/ml). 
Precleared cell lysates were then precipitated with anti-PDI or anti-CD31 as 
control.  
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After preclearing with IgG from DHF patients, cells lysates were precipitated with 
anti-PDI or mab anti-CD31. Whereas specific band for CD31 was detected, no 
PD1 protein could be precipitated by anti-PDI. This result demonstrates that 
antibody in DHF patients react with PDI on endothelial cells. 
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3.9 Inhibition of PDI abolishes HO-1 upregulation mediated by anti-NS1 
antibodies 
 
To further investigate the binding mechanism between anti-NS1 antibodies and 
PDI, bacitracin was applied as PDI inhibitor (Swiatkowska et al., 2000). 
Pretreatment of HUVEC cells with bacitracin and RL-90 caused inhibition of anti-
NS1 antibody-induced HO-1 upregulation on protein level as shown in Figures 
15 and 16, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Inhibition of PDI with bacitracin abolishes HO-1 upregulation 
mediated by anti-NS1 antibodies. HUVEC were incubated for 30 min in the 
absence or presence of 4 µl bacitracin (2 mM). After washing cells were treated 
with mab anti-NS1 (10 µg/ml), DHF IgG (10 µg/ml) or heme (1 µM) as control for 
18 h. Cells were lysed and HO-1 expression was analyzed by immunoblotting as 
described. The relative band densities were expressed as fold-induction, 
normalized to GAPDH band from three independent experiments.  
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Figure 16. Inhibition of PDI with RL-90 abolishes HO-1 upregulation 
mediated by anti-NS1 antibodies. HUVEC were incubated for 30 min in the 
absence or presence of 10 µg/ml mab RL-90 against PDI. After washing cells 
were treated with mab anti-NS1 (10 µg/ml), DHF IgG (10 µg/ml) and heme 
(1 µM) as control for 18 h. Cells were lysed and HO-1 expression was analyzed 
by immunoblotting as described. The relative band densities were expressed as 
fold-induction, normalized to GAPDH band from three independent experiments.  
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3.10  Permeability disturbance of endothelial cells by anti-NS1 antibodies 
 
To investigate whether anti-NS1 antibodies increasing endothelial permeability, 
labelled markers (albumin-FITC) through tightly confluent HUVEC monolayers 
were measured. Stimulation of HUVEC with mab anti-NS1 or IgG from DHF 
patients IgG increased transendothelial migration of albumin FITC in comparison 
to HUVEC treated with isotype control 7D8 (mab anti-CD177) or normal human 
IgG (Figure 16). 
 
Figure 17. Analysis of endothelial permeability with anti-NS1 antibodies. 
HUVEC were grown for 2 days on collagen-coated Transwell filters to 
confluence, then incubated with PBS buffer (control), isotype control (mab 7D8; 
10 µg/ml), normal IgG (10 µg/ml), DHF IgG (10 µg/ml) and mab anti-NS1 
(10 µg/ml) for 18 h. Fluorescence labeled albumin (Albumin-FITC; 40 ng/ml) 
were then added in to the upper chamber. Transwell were measured by 
fluorescence reader and expressed as percentage of the total albumin-FITC. 
Data represent means ± S.E from at least three independent experiments. 
Student’s t tests: *P<0.05 vs normal IgG.  
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CHAPTER 4 
DISCUSSION 
 
 
4.1 Anti-NS1 antibodies cause accumulation of cellular ROS, apoptosis, 
and permeability disturbance on endothelial cells  
 
Dengue haemorrhagic fever is the main cause of mortality in dengue virus 
infection (Valdes et al., 2000). Haemorrhagic syndrome, a feature of DHF is a 
hematologic abnormality resulting from multiple factors, including 
thrombocytopenia, coagulopathy and vasculopathy related with 
destruction/dysfunction of platelet and endothelial cells (Rothman et al., 1999). 
Although the exact pathomechanism is not very well defined, available data 
strongly suggest that in the most cases of DHF immune mediated mechanism 
play also an important role in the destruction of platelets and disturbance of 
endothelial function (Lin et al., 2006; Lei et al., 2008). 
 
It is well known, that antibodies against DENV can augment secondary DENV 
infection through the phenomenon called antibody-dependent enhancement 
(ADE) (Morens et al., 1994; Anderson et al., 1997). At certain concentration, 
sub-neutralizing antibodies against DENV form antigen/antibody complexes, 
which are recognized by monocytes via Fc receptors (Mady et al., 1991), leading 
to enhanced virus uptake, resulting in an increased number of virus infected cells 
(Littaua et al., 1990, Lei et al., 2001). These antibodies are IgG subclass and 
recognized DENV structural proteins such as E and prM peptides (Henchal, et 
aI, 1985). 
 
Several evidences indicated a mechanism of molecular mimicry in which 
antibodies against non-structural protein NS1 of DENV (anti-NS1 antibodies) can 
also cross react with platelet and endothelial cells, and thereby may induce 
platelet destruction and endothelial disturbance in DHF patients (Falconar et al., 
1997, Lin et al., 2004). Interestingly, Lin et al (2004) showed a strong cross-
reaction between sera from DHF/DSS with endothelial cells, but not with sera 
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from DF patients. In line with these observations, we found by the use of solid 
phase ELISA that anti-NS1 antibodies derived during acute phase of DHF 
reacted strongly with NS1 antigen as comparison to sera from DF patients.  
 
Recent study demonstrated that anti-NS1 antibodies recognize an 
immunodominant RGD- and ELK/KLE motifs of NS1 molecule, which is present 
on human clotting factors (fibrinogen, factor VII, IX, X) as well as on cell 
adhesion molecules, particularly integrin such as IIb3, v3 (Chang et al., 
2002; Falconar, 2007). However, direct binding of anti-NS1 antibodies to these 
adhesive molecules have not been well documented (Wiwanitkit, 2006).  
 
Recently Cheng et al. (2008) found that anti-NS1 antibodies react with several 
proteins on Human microvascular endothelial cells (HMEC-1) endothelial cell line 
including ATP synthase beta chain, PDI, vimentin, and heat shock protein 60. To 
identify the target antigen on endothelial cells recognized by anti-NS1 antibodies, 
we performed immunoprecipitation with surface labelled HUVEC, and found that 
anti-NS1 antibodies from DHF patients reacted with membrane protein of 62-72 
kDa corresponding to the apparent molecular weight of PDI. By the use of pre-
clearing experiment approach we could definitely identified PDI as the target 
antigen of anti-NS1 antibodies. This is in accordance with the recent study 
reported by Cheng et al. (2009). The authors demonstrated that anti-NS1 
antibodies recognized PDI on platelet surface causing inhibition of platelet 
aggregation induced by ADP. Further analysis showed that anti-NS1 antibodies 
bound to amino acid residues 311-330 of DENV NS1, which shares sequence 
homology with the thioredoxin domain of PDI.  
 
Interestingly, PDI has been shown to play a role on the regulation of integrin 
activation (Essex et al., 2006). Swiatkowska et al. (2008) showed that 
modulation of the thiol isomerase activity of PDI by divalent manganese cation 
leads to PDI/vβ3 integrin complex formation resulting in integrin-transition; from 
resting to the ligand-competent state. This mechanism may explain the 
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phenomenon of integrin co-precipitation by anti-NS1 antibodies under certain in 
vitro experimental conditions. 
 
After the identification of PDI as target antigen of anti-NS1 antibodies, there was 
any question about the functional consequence of this antibody binding for 
endothelial cell function(s). The results above were found that incubation of 
HUVEC with purified anti-NS1 from DHF IgG resulted in significance increased 
production of cellular ROS which could be specifically inhibited by the anti-
oxidant drug, NAC.  
 
It is possible that also endothelial cells contribute to ROS production during a 
dengue infection (Gil et al., 2004). It is well known that ROS can initiate and 
regulate the transcription and activation of large series of mediators in cells 
which culminate in common mechanism of cell damage including apoptosis and 
necrosis (Gil et al., 2004). ROS attack polyunsaturated fatty acid and initiative 
lipid per-oxidation which can ultimately lead to a loss or alteration of cell 
membrane function (Rothman and Ennis, 1999; Kurane and Takasaki, 2001). In 
fatal cases of DHF and DSS, cell apoptosis process of endothelial cells from 
lung and intestine tissue was observed (Limonta et al., 2007). 
 
In accordance to the previous observations described by Lin and co-workers (Lin 
et al., 2003), in this study was found that anti-NS1 antibodies can induce 
endothelial cells to undergo apoptosis. These findings suggest that ROS-
modulated endothelial cells apoptosis may disturb endothelial barrier and 
contribute thereby to the pathogenesis of vascular leakage in DHF patients. 
Indeed, we observed that treatment of endothelial cells with anti-NS1 antibodies 
caused increased penetration of fluorescence labelled albumin indicating 
leakage of barrier function of these cells which may result in spontaneous 
haemorrhage and plasma loss from the blood vessels. However, it has been 
suggested that the increased vascular permeability observed in DHF is caused 
by a malfunction rather than a structural destruction of endothelial cells 
(Rothman and Ennis, 1999; Kurane and Takasaki, 2001). 
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Generation of ROS has been detected when endothelial cells were stimulated by 
cytokines (Matsubara et al., 1986), a process which commonly occurs during 
dengue infection (Anderson et al., 1997). The cytokine secretion of dengue 
infected cells may result in activation of non-infected endothelial cells (Anderson 
et al., 1997; Halstead, 2007; Basu and Chaturvedi, 2008). High levels of TNF-α, 
IL-6 and IL-8 were measured in sera of patients with DHF/DSS (Hober et al., 
1993; Avirutnan et al., 1998; Raghupathy et al., 1998). This study showed that 
treatment of endothelial cells with TNF increased the expression of PDI on the 
cell surface. The up-regulation of PDI surface expression could facilitate the 
binding of anti-NS1 antibodies to endothelial cells, and in turns accelerate ROS 
production; a process which may decline the fate of DHF spectacularly.  
 
In line with this observation was found that inhibition of ROS production with the 
antioxidant NAC reduced basal HO-1 expression in these cells. NAC is cysteine 
analog commonly used to treat acetaminophen overdose (Kelly, 1998), NAC can 
protect against reactive oxygen species through the restoration of intracellular 
glutathione (Ratan et al., 1994; Juurlink and Paterson, 1998).  
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4.2 Anti-NS1 antibodies regulate the anti-apoptotic HO-1 on endothelial 
cells via activation of pI3K  
 
On the other hand, several reports indicate that HO-1 has a cytoprotective role 
by its ability to break down the pro-oxidant heme to the powerful anti-oxidants 
products biliverdin and bilirubin (Yi and Hazel, 2005). This effect has been 
demonstrated under both in vitro (Vile and Tyrell, 1994; Abraham et al., 1995) 
and in vivo conditions (Nath et al., 1992; Otterbein et al., 1995).  
 
HO-1, an inducible heme-degrading enzyme, exerts a potent anti-inflammatory 
effect through the production of carbon monoxide and bilirubin. Expression of 
HO-1 is up-regulated by multiple stress stimuli and the enzymatic products of 
this reaction has not only antioxidant cytoprotective, but also anti-inflammatory 
functions (Kyriakis et al., 2001; Orozco et al., 2007; Pamplona et al., 2007; 
Chora et al., 2007; Chung et al., 2008). 
 
Major functions of HO-1 comprise the degradation of the pro-oxidant heme and 
the production of bilirubin, which provide protection of tissue and organs against 
oxidative stress (Abraham et al., 1988; Maines et al., 1997). More recently, HO-1 
turns to be an important modulator of the inflammatory response possibly via the 
generation of second messenger gas CO (Otterbein et al., 2002; 2003). 
Accumulation data indicate that modulation of HO-1 may not only serve as 
therapeutic target for heme-induced inflammation diseases (Willis et al., 1996; 
Wagener et al., 2001), but also has therapeutic implications in organ 
transplantation. Several studies demonstrated that the induction of HO-1 activity 
prevents the development of vascular lesions, intra-graft apoptosis, and 
significantly prolongs allograft survival (Soares et al., 1998; Hancock et al., 1998; 
Immenschuh and Ramadori et al., 2000).  
 
Recently Iwasaki et al. (2010) demonstrated that the ligation of HLA class I 
antigen on endothelial cells by low concentration of HLA class I antibodies 
protects endothelial cell against complement destruction by induction of HO-1 
gene in a PI3K/Akt dependent manner.  
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The present study found that purified anti-NS1 antibodies from DHF patients 
caused specific induction of HO-1 in endothelial cells which can be inhibited by 
soluble recombinant NS1 antigen underlying the importance of this mechanism 
in endothelial cells. In addition, we could demonstrate that pI3K signaling 
pathway is also involved in the HO-1 regulation mediated by anti-NS1 antibody. 
Treatment of HUVEC cells with specific pI3K inhibitors (LY294002 and 
Wortmanin) blocked significantly anti-NS1 antibodies-mediated HO-1 
expression. In addition, stimulation of endothelial cells with anti-NS1 antibodies 
caused an elevation of Akt-phosphorylation, which was specifically inhibited by 
pI3K inhibitors.  
 
It is known that HO-1 is inducible during the oxidative stress caused for example 
by different substances which are able to modify intracellular glutathione levels 
(Applegate and Philip, 1991). In line with this observation, this study found that 
inhibition of ROS production with the antioxidant NAC resulted in dose-
dependent reduction of basal HO-1 expression.  
 
NAC is a cysteine analog commonly used to treat acetaminophen overdose 
(Kelly, 1998). Studies in the past documented that NAC protects cells against 
ROS through the restoration of intracellular glutathione (Ratan et al., 1994; 
Juurlink & Paterson, 1998). Treatment with NAC results in a rapid recovery of 
reduced glutathione level in brain and reduction of oxidative stress following in 
traumatic brain injury (Juurlink and Paterson, 1998; Xiong et al., 1999).  
 
In this study it was found that Anti-NS1 antibodies increased the generation of 
intracellular ROS and up-regulated the expression of HO-1, and suppressed by 
the pretreatment with NAC. It is likely that NAC acts as a scavenger for some 
specific anti-NS1 antibody-induced oxidative reaction that triggers HO-1 
induction.  
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Figure 18. Possible mechanism of endothelial leakage induced by anti-NS1 
antibodies. In one site, binding of anti-NS1 antibodies to endothelial cell surface 
via PDI causes ROS production leading to apoptosis and integrin activation 
(v3) which may result in disturbance of cellular haemostasis. Another side, 
this interaction induces consequently down stream signalling via pI3K signalling 
pathway which resulted in the upregulation of the anti-apoptotic HO-1. Thus, the 
balance between ROS secretion and the production of HO-1 (anti-apoptotic) 
induced by anti-NS1 antibodies is important for the regulation of vascular 
leakage and for the prevention of irreversible endothelial damage in DHF 
patients.  
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In overall, this information provides new insight into the molecular mechanism of 
antibody mediated endothelial disturbance in DHF. This knowledge may help us 
to define a new therapeutic strategy for the patients with DHF. 
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CHAPTER 6 
SUMMARY  
 
 
Dengue haemorrhagic fever (DHF) is characterized by thrombocytopenia, 
increased vascular permeability and haemorrhage. The antibody against NS1 of 
the dengue virus seems to play a role in the pathogenesis of dengue virus 
disease due to its cross-reaction with endothelial cells. Recently, it has been 
demonstrated that anti-NS1 antibodies induced endothelial cells to undergo cell 
apoptosis. However, the exact mechanism underlying this antibody-mediated cell 
apoptosis is not well-known. 
 
In this study, the influence of anti-NS1 antibodies of DHF patients on the 
regulation of HO-1 in HUVEC was investigated. Sera derived from DHF patients 
with or without anti-NS1 antibodies were analyzed. Incubation of HUVEC with 
purified anti-NS1 antibodies from dengue virus infected patients caused HO-1 
upregulation in a time and dose manner which was attenuated by the NS1 
antigen. This upregulation was not observed with IgG from patients without NS1 
antibodies. Furthermore, reduction of HO-1 was observed, when HUVEC were 
pretreated with pI3K pathway inhibitors (LY294002 and wortmannin) prior to 
stimulation with anti-NS1 antibodies. In contrast, no inhibition was detectable 
with p38 MAPK inhibitors (SB203580). These results indicate that the pI3K 
signaling pathway plays a major regulatory role for the induction of HO-1 by anti-
NS1. 
 
In addition, stimulation of HUVEC with anti-NS1 antibodies induced the 
production of ROS, induced endothelial cell apoptosis, and increased cell 
permeability. These mechanisms probably contribute to the pathomechanism of 
vascular leakage and haemorrhage, which is often clinically observed in dengue 
fever patients.  
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Protein disulfide isomerase (PDI) was found expressed on the endothelial 
surface as a target antigen for anti-NS1 antibodies by the use of 
immunoprecipitation approaches and flow cytometry analysis.  
 
Taken together, this study indicates that anti-NS1 antibodies bind to endothelial 
cells via PDI as a surface target protein. This interaction leads to production of 
ROS which can induce cell apoptosis and disturbance of endothelial cell 
permeability. On the other hand, ROS initiates the induction of the anti-apoptotic 
gene HO-1 via the pI3K signalling pathway. Thus, the balance between ROS 
(apoptotic) and HO-1 (anti-apoptotic) production induced by anti-NS1 antibodies 
may have significance as the cause of vascular leakage in some DHF patients.  
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CHAPTER 6 
ZUSAMMENFASSUNG 
 
 
Das Dengue Hämorrhagische Fieber (DHF) geht mit Thrombozytopenie, 
erhöhter Gefäßpermeabilität und Blutungen einher. Der Antikörper gegen das 
Nicht-Struktur-Protein NS1 des Dengue Virus scheint in der Pathogenese der 
Erkrankung eine Rolle aufgrund seiner Kreuzreaktion mit Endothelzellen zu 
spielen. Kürzlich wurde gezeigt, dass anti-NS1 in Endothelzellen Apoptose 
veranlasst. Der genaue Mechanismus hierfür ist jedoch nicht bekannt. 
 
In dieser Studie untersuchten wir den Einfluss von NS1-Antikörpern von DHF-
Patienten auf die Regulierung von HO-1 in HUVEC in vitro. Die Inkubation von 
HUVEC mit gereinigtem anti-NS1-IgG verursachte einen dosisabhängigen 
Anstieg von HO-1, der mit IgG von Patienten ohne NS1-Antikörper nicht 
beobachtet wurde. Dagegen wurde eine Abnahme von HO-1 beobachtet, wenn 
die PI3K-Signalkaskade-Inhibitoren LY294002 oder Wortmannin vor der 
Behandlung mit anti-NS1 verabreicht wurden. Im Gegensatz dazu war ein 
solcher Effekt nicht mit dem p38 MAPK-Inhibitor SB203580 feststellbar. Diese 
Ergebnisse zeigen die Beteiligung von PI3K an der Signalkaskade des anti-NS1-
vermittelten HO-1-Anstiegs. 
 
Zusätzlich veranlasste die Behandlung von HUVEC mit dem anti-NS1-Antikörper 
die Produktion von ROS, die Zunahme von Apoptosen und eine erhöhte 
Permeabilität der Endothelzellen. Diese Mechanismen tragen wahrscheinlich 
zum Pathomechanismus der stark erhöhten Gefäßpermeabilität bei, die klinisch 
bei Dengue Fieber-Patienten öfter zu beobachtenist.  
 
Als Gegenmechanismus verursacht ROS aber über die Induktion von HO-1 via 
PI3K/Akt-Signalkaskade (siehe oben) auch eine anti-apoptotische Wirkung. So 
kann das Gleichgewicht zwischen der direkten Wirkung von ROS 
(Apoptoseinduktion) und anti-apoptotischer Wirkung des anti-NS1-Antikörpers 
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über HO-1 wichtig für die Ausprägung der Gefäßpermeabilitätserhöhung bei 
DHF-Patienten sein. 
 
Weiterhin konnte in dieser Arbeit als Zielantigen der anti-NS1-Antikörper auf 
Endothelzellen die Protein-Disulfidisomerase (PDI) nachgewiesen werden. 
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